Epigenetic drugs witness 375% growth in series A venture financing in 2024YTD, reveals GlobalData
GlobalData’s Pharma Intelligence Center Deals Database reveals that companies developing epigenetic drugs received over $1 billion in total series A venture financing from 2019 to 2024YTD